華潤三九(000999.SZ):示蹤用鹽酸米託蒽醌注射液獲批上市
格隆匯6月23日丨華潤三九(000999.SZ)公佈,公司控股子公司深圳華潤九創醫藥有限公司近日收到國家藥品監督管理局頒發的關於示蹤用鹽酸米託蒽醌注射液(商品名:復他舒)的《藥品註冊證書》(證書編號:2021S00714)。
示蹤用鹽酸米託蒽醌注射液屬於2類新藥,入選國家“十三五”重大新藥創制科技重大專項,注射本品到腫瘤周緣組織後能夠靶向區域淋巴結並將其藍染,從而起到淋巴示蹤的作用,可廣泛適用於甲狀腺癌等區域引流淋巴結示蹤。本品為國內首個正式批准用於甲狀腺手術區域引流淋巴結的示蹤的產品,經臨牀驗證本品具有良好的安全性和淋巴示蹤效果,同時對甲狀旁腺特異性不染色,可顯著降低甲狀旁腺誤切,具有重要的臨牀價值。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.